This is Mariano Barbacid, the scientist who may have discovered the cure for pancreatic cancer.

By557646pwpadmin

Mariano Barbacid: The Architect of a Pancreatic Cancer Breakthrough

You are exactly right—Mariano Barbacid is currently the name on everyone’s lips in the scientific community. As of late January 2026, he and his team at the Spanish National Cancer Research Centre (CNIO) have published a study that is being hailed as a historic milestone in oncology.

While “cure” is a heavy word in medicine, what Barbacid has achieved is arguably the closest we have come for this specific, deadly disease.

The Discovery: The “Triple Threat” Therapy

For decades, pancreatic cancer has been “undruggable” because it adapts too quickly. If you block one pathway, the tumor finds another. Barbacid’s breakthrough, published in the journal PNAS on January 27, 2026, uses a “three-pronged” attack to trap the cancer:

  1. Daraxonrasib: An experimental drug that blocks the primary growth signal (KRAS), which is mutated in 90% of pancreatic cancers.

  2. Afatinib: A drug (already used for lung cancer) that shuts down the EGFR and HER2 pathways—the “escape routes” the cancer usually takes when KRAS is blocked.

  3. SD36: A “protein degrader” that disables STAT3, the tumor’s emergency backup system for surviving stress.

The Results

In mouse models that precisely mimic human pancreatic cancer, the results were unprecedented:

  • 100% Elimination: The tumors didn’t just shrink; they completely disappeared.

  • No Relapse: Even 200–300 days after the treatment stopped (a lifetime in mouse terms), the cancer did not return.

  • Low Toxicity: Unlike traditional chemotherapy, the mice tolerated this triple-drug cocktail with very few side effects.

A Note of Peer-to-Peer Candor

While the internet is buzzing with the word “cure,” it is important to ground the hype. Barbacid himself has been very direct in interviews this week: “We are not yet in a position to carry out clinical trials in humans.”

  • The Gap: What works in mice doesn’t always translate to the complex human immune system.

  • The Goal: This study provides the “blueprint.” The next 1–2 years will be focused on optimizing these drugs for human safety trials.

The Man Behind the Science

At 76 years old, Barbacid is a titan of science. In 1982, he was the first to isolate a human oncogene (a gene that can turn a cell into a tumor). This 2026 discovery is essentially the “full circle” moment of his 40-year career.

A Sad Side Note: Despite his world-changing work, Barbacid recently went viral for a different reason—he was targets of shallow social media bullying regarding a birthmark on his face. Thankfully, the scientific community rallied around him, reminding the world that his mind is what matters, not his appearance.